Effects of polycystic ovary syndrome on liver, heart, muscle, and pancreatic-related diseases - Summary - MDSpire

Effects of polycystic ovary syndrome on liver, heart, muscle, and pancreatic-related diseases

  • By

  • Bingrui Li

  • Yuan Li

  • Xianglin Li

  • Zicheng Yu

  • Jin Yu

  • Yang Shao

  • Tonglu Li

  • Shuai Sun

  • Ling Zhou

  • Ruipin Yao

  • Wen Cheng

  • Jing Zhu

  • Jindong Miao

  • You Li

  • Yang Wu

  • Yin Shi

  • Jing Zhou

  • Chaoqin Yu

  • Changquan Ling

  • April 10, 2026

  • 0 min

Share

Objective:

To explore the systemic metabolic effects of PCOS beyond reproductive dysfunction, specifically its impact on liver, cardiac, muscular, and pancreatic health.

Key Findings:
  • PCOS prevalence is 28.3% in obese women.
  • 51.61% of obese PCOS patients develop metabolic dysfunction–associated steatotic liver disease (MASLD).
  • Cardiovascular disease and type 2 diabetes risks are elevated 2–4 fold in PCOS patients.
  • Multi-organ dysfunction, including sarcopenia, is linked to a cycle of androgen excess and metabolic disturbances.
Interpretation:

PCOS is a systemic metabolic disorder that affects multiple organs, necessitating an integrated approach to management that addresses the interconnected nature of its complications.

Limitations:
  • Limited studies specifically addressing muscle involvement in PCOS; further research is needed to clarify the mechanisms linking PCOS to pancreatic cancer risk.
Conclusion:

A shift towards multidisciplinary management is essential to address the comprehensive health impacts of PCOS, considering its systemic nature.

Original Source(s)

Effects of polycystic ovary syndrome on liver, heart, muscle, and pancreatic-related diseases

  • by Bingrui Li, Yuan Li, Xianglin Li, Zicheng Yu, Jin Yu, Yang Shao, Tonglu Li, Shuai Sun, Ling Zhou, Ruipin Yao, Wen Cheng, Jing Zhu, Jindong Miao, You Li, Yang Wu, Yin Shi, Jing Zhou, Chaoqin Yu, Changquan Ling

  • April 10, 2026

Related Content

Outcome-specific shifts in homocysteine-androgen correlations in polycystic ovary syndrome

A Case Report: Treatment, follow-up, and literature review of type A insulin resistance syndrome caused by a De Novo INSR c.3328G>C mutation

The role of metabolic reprogramming in oocyte development: research progress and prospects